Premium
Routine screening for HIV , hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery
Author(s) -
Assoumou L,
Thormann F,
Soulié C,
Caby F,
Dudoit Y,
Marcelin AG,
Goudot P,
Blanc C,
Coriat P,
Katlama C,
Costagliola D,
Pourcher V
Publication year - 2019
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12732
Subject(s) - medicine , odds ratio , hepatitis c virus , hepatitis b virus , confidence interval , hepatitis c , hepatitis b , immunology , virus
Objectives Given the effectiveness of treatment of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, there are considerable benefits associated with determining HIV / HBV / HCV status. We evaluated the feasibility and acceptability of systematic screening and subsequent care in an oral and maxillofacial surgery department. Methods The anaesthesiologists proposed screening for HIV , HBV and HCV to all individuals of unknown infection status undergoing surgery between 19 April 2016 and 19 April 2017. The endpoints were the rates of test offer, acceptance/refusal and new diagnoses. Seropositive individuals were referred to infectious disease specialists. Associations between age, sex or surgery type and test offer (eligible individuals) or acceptance/refusal (those offered testing) were investigated. Results Of the 1407 individuals attending the department, 1322 were eligible for inclusion in the study. Testing was proposed to 899 individuals [68%; 95% confidence interval ( CI ) 65–71%], 831 of whom accepted the offer (92.4%; 95% CI 90.5–94.1%). Results were obtained for 787 individuals (41 samples were uncollected and three were invalid). Age was the only factor associated with test offer in multivariable analysis [odds ratio ( OR ) 0.90; 95% CI 0.84–0.97, per additional 10 years], and no factor was associated with acceptance. Of the five, three and eight individuals testing positive for HIV , HBV and HCV , four, two and one patient, respectively, reported prior knowledge of seropositivity. The new diagnosis rate was 0.13% (95% CI 0–0.7%) for HIV and HBV , and 0.89% (95% CI 0.36–1.82%) for HCV [three positive polymerase chain reaction ( PCR ) tests]. All individuals newly diagnosed with HIV or HCV infection received specific antiviral treatment. Conclusions Rates of screening offer and acceptance were high. Substantial screening resources are required to decrease the impact of the hidden epidemics of HIV , HBV and HCV infections.